An optimized dosing regimen of cimaglermin (neuregulin 1β3, glial growth factor 2) enhances molecular markers of neuroplasticity and functional recovery after permanent ischemic stroke in rats

Cimaglermin (neuregulin 1β3, glial growth factor 2) is a neuregulin growth factor family member in clinical development for chronic heart failure. Previously, in a permanent middle cerebral artery occlusion (pMCAO) rat stroke model, systemic cimaglermin treatment initiated up to 7 days after ischemi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Neurosci Res
Main Authors: Iaci, Jennifer F., Parry, Tom J., Huang, Zhihong, Pavlopoulos, Elias, Finklestein, Seth P., Ren, Jingmei, Caggiano, Anthony
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2015
Fag:
Research Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4737294/
https://ncbi.nlm.nih.gov/pubmed/26660233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jnr.23699
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker